Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.
In an "Executive Decision" segment, Cramer sat down with Kevin Conroy, chairman, president and CEO at Exact Sciences (EXAS - Get Report) , to discuss his company's new non-invasive test for colon cancer, Cologuard. Shares of Exact Sciences are up 187% year to date.
Conroy said Cologuard is a "big deal" because it's both easy and accurate, and it brings peace of mind to to everyone who gets a "normal" result from the test. He said that screening and early detection is critical for colon cancer and Cologuard costs just $500, compared to between $1,500 and $5,000 for a traditional colonoscopy procedure.
When asked about his company's pricing strategy, Conroy said that Medicare is the largest payer for Cologuard and Exact Sciences believes that no one should pay less than the government for these tests.
Exact Sciences is also developing a new test to detect pancreatic cancer that uses the same technology as Cologuard, Conroy added.
Cramer said he's a believer in Exact Sciences.
Meanwhile, over on Real Money, global equity and income columnist Antonia Oprita says the payrolls data sent a few shivers through the markets. Read more and get a free trial subscription to Real Money.
Cramer and the AAP team have their weekly roundup ready. Find out what they're telling their investment club members about key holdings Hewlett-Packard Enterprises (HPE - Get Report) , Snap-On (SNA - Get Report) , Starbucks (SBUX - Get Report) and more. Get a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To read a full recap of this episode of "Mad Money," click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.